Core Viewpoint - Hims & Hers Health Inc. has decided to stop selling its copycat version of Wegovy's weight-loss pill following regulatory scrutiny from the FDA and pressure from Novo Nordisk [1][3]. Group 1: Company Actions - Hims announced plans to launch a cheaper version of Novo Nordisk's Wegovy weight-loss pill but has since halted sales after discussions with stakeholders [1][2]. - The FDA is investigating Hims for potential violations of federal law regarding the sale of copycat weight-loss treatments [3]. Group 2: Industry Context - The FDA has faced criticism from major pharmaceutical companies like Novo and Eli Lilly for not adequately addressing the proliferation of cheaper, compounded weight-loss drugs [4]. - Hims has previously experienced friction with Novo, including a failed partnership over discounted weight-loss shots due to compounding issues [5]. Group 3: Leadership Statements - Hims CEO Andrew Dudum expressed a strong stance against complying with pharmaceutical companies' demands regarding copycat weight-loss drugs, indicating a commitment to their business strategy [6].